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Abstract Phospholipase A2 (PLA2) is a group of enzymes
that hydrolyze the sn-2 position of glycerophospholipids to
yield fatty acids and lysophospholipids. Of many PLA2so r
related enzymes identified to date, secreted PLA2s
(sPLA2s) comprise the largest family that contains 10
catalytically active isozymes. Besides arachidonic acid
released from cellular membranes for eicosanoid synthesis,
several if not all sPLA2s have recently been implicated in
hydrolysis of phospholipids in lipoprotein particles. The
sPLA2-processed low-density lipoprotein (LDL) particles
contain a large amount of lysophospholipids and exhibit the
property of “small-dense” or “modified” LDL, which
facilitates foam cell formation from macrophages. Trans-
genic overexpression of these sPLA2s leads to development
of atherosclerosis in mice. More importantly, genetic
deletion or pharmacological inhibition of particular sPLA2s
significantly attenuates atherosclerosis and aneurysm. In
this article, we will give an overview of current under-
standing of the role of sPLA2s in atherosclerosis, with
recent lipidomics data showing the action of a subset of
sPLA2s on lipoprotein phospholipids.
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Abbreviations
ESI-MS Electrospray ionization-mass spectrometry
HDL High-density lipoprotein
LDL Low-density lipoprotein
LPA Lysophosphatidic acid
LPC Lysophosphatidylcholine
LPE Lysophosphatidylethanolamine
PC Phosphatidylcholine
PG Prostaglandin
PUFA Polyunsaturated fatty acid
SM Sphingomyelin
sPLA2 Secreted phospholipase A2
Classification of sPLA2s
The sPLA2 family represents structurally related, disulfide-
rich, low molecular weight, lipolytic enzymes with a His-
Asp catalytic dyad. sPLA2s occur in a wide variety of
vertebrate and invertebrate animals, plants, bacteria, and
viruses, and 10 catalytically active sPLA2 isozymes (IB,
IIA, IIC, IID, IIE, IIF, III, V, X, and XIIA) are identified in
mammals. Of these, sPLA2s belonging to the group I/II/V/
X collection are closely related 14–19-kDa proteins of
secreted enzymes with a highly conserved Ca
2+-binding
loop and a His-Asp catalytic site. In addition to these
elements, there are six absolutely conserved disulfide bonds
and up to two additional unique disulfide bonds, which
contribute to the high degree of stability of these enzymes.
Group III and group XII sPLA2s share little homology with
the I/II/V/X collection of sPLA2s except for the Ca
2+-binding
loop and the catalytic site, thereby representing the distinct
group collections. Unlike intracellular PLA2s, sPLA2s
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millimolar concentrations of Ca
2+, suggesting that they
primarily act on “extracellular” substrates. Since individual
sPLA2s display distinct cellular/tissue distributions and
substrate head group/fatty acid specificities, they may play
non-redundant, isoform-specific roles in vivo. The latest
biochemistry and biology of the sPLA2 family have been
detailed in recent reviews [1, 2].
Lipoprotein hydrolysis by sPLA2s: in vitro studies
Lipoprotein modification and atherosclerosis;
a general view
A lipoprotein is a biochemical assembly that contains both
proteins and lipids whose function is to transport water-
insoluble lipids in the water-based bloodstream. Examples
include the high-density (HDL) and low-density (LDL)
lipoproteins, which enable fats to be carried between the
blood and tissues. Since higher levels of LDL particles
promote health problems and cardiovascular disease typically
known as atherosclerosis, they are often called the bad
cholesterol particles, as opposed to HDL particles that are
frequently referred to as good cholesterol or healthy
cholesterol particles. LDL particles vary in size and density,
and studies have shown that high plasma levels of small
dense LDL particles rather than larger and less dense LDL
particles well correlate with a higher risk for coronary heart
disease. The surfaces of LDL and HDL are surrounded by
phospholipids, mainly phosphatidylcholine (PC), which, as a
matter of fact, serves as a very good “extracellular” target of
several if not all sPLA2 isoforms.
It has been believed that a key step of pro-atherogenic
small-dense LDL generation is oxidative modification of the
polyunsaturatedfattyacids(PUFAs)inphospholipidsonLDL
surface. However, the “oxidation hypothesis of atherosclero-
sis” [3] still remains inconclusive, as oxidation alone cannot
fully explain the accumulation of large amounts of lipids and
lysophosphatidylcholine (LPC) in foam cells and fatty streak
lesion formation [4]. Current knowledge suggests that
sPLA2-mediated modification of lipoproteins plays a role in
the development of atherosclerosis [5, 6]. This idea originally
arose from the following key observations. Hydrolysis of PC
in lipoproteins by sPLA2 produces free fatty acids (typically
unsaturated) and LPC, which can trigger vasoactive, chemo-
tactic, and pro-inflammatory actions leading to the accelera-
tion of atherosclerosis. Hydrolysis of LDL by sPLA2
correlates with production of the more atherogenic, small-
dense, modified LDL with increased net negative charge,
whereas hydrolysis of HDL reduces the capacity of this anti-
atherogenic particle to promote cholesterol efflux from lipid-
rich foam cells. Modified LDL retained in atherosclerotic
lesions contains less PC and more LPC than does circulating
LDL, suggesting that arterial LDL undergoes lipolytic
modification by certain extracellular PLA2 enzyme(s) at
lesion sites. Further, clinical analyses have shown that
elevated plasma PLA2 activity (likely sPLA2-IIA) is an
independent risk factor for cardiovascular disease [7, 8], and
a low content of surface phospholipids often characterizes the
small-dense LDL and HDL subclasses [9].
Hydrolysis of lipoprotein-bound phospholipids by
sPLA2s can give rise to the two pro-atherogenic and pro-
inflammatory lipid products, lysophospholipids and fatty
acids. LPC modulates the expression of a number of
proteins such as cytokines, chemokines, growth factors,
adhesion molecules, inducible nitric oxide synthase and
cyclooxygenase-2 [10]. LPC plays an ethiologic role in
atherosclerosis, is a major constituent of atherogenic
lipoproteins [11], and exhibits pro-inflammatory functions
including activation of macrophages as well as induction of
chemotactic factors and adhesion molecules in endothelial
cells [12]. Lysophosphatidic acid (LPA), an autotaxin-
hydrolyzed product of LPC that elicits numerous effects
on cells of the cardiovascular system, induces the formation
of arterial neointima lesions, a prelude of atherosclerosis,
through the PPARγ-dependent mechanism [13]. LPA
accumulates in the lipid-rich core of human carotid
atherosclerotic plaques [14]. Arachidonate-oxygenated lipid
mediators, including prostaglandins (PGs) and leukotrienes,
also have diverse effects on atherosclerosis, as evidenced
by studies employing knockout mice for their receptors or
biosynthetic enzymes. For instance, gene ablation of
thromboxane A2 receptor or PGE2 synthase ameliorates,
whereas that of PGI2 receptor or PGD2 synthase exacer-
bates, the experimental atherosclerosis in mice [15–17].
Mice lacking 5- or 12/15-lipoxygenase are also partially
protected from the development of atherosclerosis [18, 19].
Thus, increased production of these pro-atherogenic lipid
mediatorsmayaccount,atleastinpart,forthepro-atherogenic
actionofsPLA2s. A proposed idea for the mechanistic action
of sPLA2s on the development of atheroslcerosis is
illustrated in Fig. 1.
However, a series of initial studies describing the
relationship among sPLA2, lipoprotein hydrolysis and
atherosclerosis have some concerns that should be inter-
preted more carefully. First, many studies using sPLA2s
from snake or bee venom could be misleading, since the
properties of venom sPLA2s are distinct from those of
mammalian sPLA2s. Second, even if mammalian sPLA2s
were used, their concentrations employed were often very
high (>100 nM) that could be out of the physiological level.
Third, many investigators had an incorrect recognition that
a l lo rm o s tm a m m a l i a ns P L A 2s are induced during
inflammation and can exist in the plasma. However, it is
only sPLA2-IIA that is strongly induced under pathologic
1830 K. Yamamoto et al.conditions associated with inflammation, tissue injury or
infection, and actually there have been no convincing
reports that other sPLA2 isoforms are present in the
circulation [1, 2]. Fourth, although LPC released by sPLA2s
from lipoprotein particles has been proposed to be a critical
inducer of atherosclerotic cellular events, LPC already
exists in the plasma at a very high level (as much as
hundreds μM). Finally, considering the recent concept that
atherosclerosis is a mild and chronic inflammation in the
arterial wall [20], pro-inflammatory changes, in addition to
modification of lipoproteins, in the plaques should be taken
into consideration as a causal factor in which sPLA2s might
be involved. Nevertheless, the physiological relevance of
the potential contribution of sPLA2s to atherosclerosis is
recently being elucidated by several elegant studies
employing sPLA2 gene-manipulated mice as well as an
sPLA2-targeted small molecule inhibitor, as described later.
Application of mass spectrometry in analyzing sPLA2
hydrolysis of lipoprotein-bound phospholipids
In the past five years, several studies have examined the
hydrolytic activity of human sPLA2st o w a r dL D L -o rH D L -
associated phospholipids using mass spectrometry (MS).
These approaches have delineated the fundamental differences
in lipoprotein hydrolysis by distinct human sPLA2s. Several
quantitative analyses have shown that sPLA2-Vand -X are 20
~30 times more reactive on PC in HDL and LDL than
sPLA2-IB and -IIA [21–23]. Interestingly, sPLA2-X hydro-
lyzes arachidonate- and linoleate-containing PC species
preferentially, group V hydrolyzes oleoyl- and linoleate-PC
in preference to arachidonate-PC, and sPLA2-IIA hydrolyzes
randomly all diacyl molecular species. The hydrolysis of
minor phospholipid species (e.g. phosphatidylinositol and
phosphatidylserine) in HDL and LDL by sPLA2-V and -X is
low relative to that of PC [24]. As a result, these acidic
phospholipids remain at higher levels in both LDL and HDL,
thereby increasing the acidity of the modified particles.
Although the activity of sPLA2-IIA on lipoproteins is
relatively weak (also see below), it can hydrolyze acute phase
HDL 2~3-fold more efficiently than normal HDL, with
preferential attack on PC with oxygenated PUFAs [25]. LDL
hydrolysis by sPLA2s is also affected by the contents of other
lipid components such as sphingomyelin (SM) and neutral
lipids, since higher percentages of SM interfere with LDL
hydrolysis by sPLA2-IIA and -V [22] and since LDL from
patients with type 2 diabetes is more susceptible than that
from normal subjects to sPLA2-V hydrolysis [26, 27].
We performed electrospray ionization MS (ESI-MS) to
directly compare the hydrolytic activity of six human
sPLA2 isoforms, IIA, IIE, IIF, III, V and X, on PC in
human LDL and HDL particles (for more details, please see
[28]). Both LDL and HDL particles contained three major
PC molecular species (C16:0–18:2, C18:0–18:2 and
C18:0–20:4) and only trace levels of LPC molecular species
Fig. 1 A proposed role of sPLA2 in the development of atheroscle-
rosis. In the arterial wall, multiple sPLA2s are present in macrophages
and smooth muscle cells as well as in the extracellular matrix. LDL
captured by the extracellular matrix proteoglycan is hydrolyzed by
proteoglycan-bound (IIA and V) or -unbound (III and X) sPLA2st ob e
converted to small-dense LDL, which in turn facilitates macrophage
foam cell formation and thereby atherosclerosis development. Free
fatty acids (FFA) and LPC or their metabolites, released by sPLA2s
from LDL, can activate macrophages and smooth muscle cells and
promote collagen deposition in the atherosclerotic plaques. Additional
effects of sPLA2s within the plaques should also be considered. For
details, please see the text
Secreted phospholipase A2 1831(C16:0 and C18:0). When LDL was treated with a low
concentration (10 nM) of sPLA2sf o r4h ,t h r e es P L A 2s,
namely III, V and X, robustly increased both LPC species
(Fig. 2a). The capacities of these three enzymes to produce
LPC and lysophosphatidylethanolamine (LPE) from LDL
were nearly comparable (Fig. 2b). Marked increases of LPC
species were also observed when HDL was incubated with
10 nM sPLA2-Vor -X, whereas the activity of sPLA2-III on
HDL-bound PC at this concentration was modest even
though significant (Fig. 3a). Notably, all PC species were
dramatically reduced by sPLA2-X, linoleate-containing PC
species were reduced in preference to arachidonate-containg
PC by sPLA2-V, and arachidonate-containing PC was
preferentially reduced by sPLA2-III, revealing differences
in the potency and fatty acid selectivity of these three
sPLA2s on HDL-associated PC. In addition to LPC, LPE
was also greatly increased when HDL was treated with
sPLA2-Vor sPLA2-X, and to a lesser extent with sPLA2-III
(Fig. 3b). The ability of sPLA2-IIA and -IIE to hydrolyze
PC in LDL and HDL was minimal even at 50 nM, while
sPLA2-IIF at this concentration showed significant activity
with hydrolysis of arachidonate-PC to produce C16:0-LPC
in LDL and to produce both C16:0- and C18:0-LPC in HDL
(Fig. 4).
Taking these results altogether, the rank order of the
hydrolytic potency of various human sPLA2s, as evaluated
by ESI-MS, is X > V > III > IIF > IIA, IIE for both LDL
and HDL. This order appears to roughly correlate with their
ability to interact with PC-rich vesicles and with PC-rich
cellular plasma membranes [1, 2]. Note that, although
sPLA2-IIA did not show a detectable level of activity in our
experimental setting (see above), previous studies employing
very high concentrations of sPLA2-IIA have shown that it
could hydrolyze lipoprotein-bound PC to some extents,
particularly oxidized lipoproteins [25, 29, 30]. Since the
expression level of sPLA2-IIA is considerably higher than
those of other sPLA2s and it is the only sPLA2 isoform
detected in the circulation of mammals (except mice) [1, 2],
it is still plausible that sPLA2-IIA participates in atheroscle-
rotic lipoprotein hydrolysis in vivo, as discussed below.
Cellular actions of sPLA2-treated LDL
Atherosclerosis, and the resulting coronary heart disease
and cerebral stroke, represent one of the most common
causes of death in industrial nations. Cholesterol-engorged
macrophages and their detritus following cell death comprise
a major volume of early fatty streak plaques as well as the
most typical advanced lesions of arteries. Unregulated uptake
of cholesterol by macrophages results in the accumulation of
multiple lipid droplets leading to the aptly named “foam cell”
phenotype [31]. Numerous studies have described a variety
of foam cell responses that would contribute to the growth
and rupture of the vessel wall plaques of atherosclerosis, and
the cholesterol-loaded macrophages appear to contribute to
the inception of the process, the lethal conclusion in plaque
rupture, and the triggering of the occlusive thrombosis [32].
Oxidized LDL, a generally recognized form of modified
LDL, is believed to bring about in the sub-endothelial space
where circulating anti-oxidant defense are less effective.
Mildly oxidized LDL can stimulate the release of chemo-
kines by endothelial cells, increase the adherence and
penetration of monocytes, and induce scavenger receptor A
(SR-A) and CD36 expression in macrophages [33–35].
Extensively oxidized LDL becomes a ligand for SR-A and
other scavenger receptors that contribute to foam cell
formation by facilitating uptake of lipoprotein particles.
The sPLA2-hydrolyzed LDL particles, with increased
LPC contents and small diameter, can potently promote
lipid droplet accumulation in macrophages, a process
reminiscent of foam cell formation [28, 36, 37]. Indeed,
as does oxidized LDL, sPLA2-modified LDL shows some
typical features of pro-atherogenic particles, such as
increased affinity for matrix proteoglycans and propensity
of aggregation [36, 38]. Association of sPLA2-IIA or -V
with matrix proteoglycans increases the hydrolysis of
LDL-associated PC [39–41]. Furthermore, treatment with
sPLA2-IIA renders LDL more susceptible to oxidative
modification and increases its affinity for matrix proteo-
glycans. Conceivably, the close spatial contact between
sPLA2-IIA and LDL on proteoglycans may allow their
efficient interaction, and sPLA2-IIA can promote aggre-
gation and fusion of the proteoglycan-bound LDL, leading
to progressive deposition of lipids within the extracellular
matrices of the arterial intima, a central feature of
atherosclerosis [39–41]. Uptake of sPLA2-V-treated LDL
by macrophages depends on binding to syndecan 4, a
cellular proteoglycan, rather than to the scavenger receptors
SR-A and CD36 [41, 42]. LDL lipolysis by sPLA2-V results
in production of free fatty acids such as oleic and linoleic
acids, which augment TNFα and IL-6 secretion by macro-
phages [43]. Lipolytic modification of HDL by sPLA2-V
or -X reduces its capacity to promote cholesterol efflux
from lipid-loaded macrophages, thereby reducing its anti-
atherogenic function [44]. The sPLA2-modified LDL can
also affect the function of endothelial cells. The pan-sPLA2
Fig. 2 Hydrolysis of human LDL by recombinant human sPLA2-III, -V
and –X in vitro. After LDL (1 mg/ml) was incubated with or without 10
or 50 nM sPLA2 for 4 h at 37°C, lipids were extracted and applied to
ESI-MS (4000Q TRAP; Applied Biosystems), as described previously
[75, 76]. Representative results of ESI-MS for choline-containing
phospholipids on a positive ion mode (a) and lysophospholipids on a
negative ion mode (b) are shown. Major peaks of PC, LPC, LPE and
SM molecular species are indicated. Asterisks indicate the peaks that
were significantly changed by addition of each sPLA2. Top-right graphs
show quantified data of LPC and LPE. For more details, please see [28]
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ciated inflammatory responses (such as NF-κBa c t i v a t i o n
and chemokine production) in TNFα-stimulated human
endothelial cells, which express sPLA2-V [45]. Also, LDL
modified by sPLA2-X increases the endothelial expression of
leukocyte adhesion molecules [46].
Although these studies emphasize the pro-inflammatory
(and thereby pro-atherosclerotic) aspects of sPLA2s, the
opposite, anti-inflammatory aspect of these enzymes should
also be taken into account. Indeed, the biological actions of
sPLA2-V, -X and -IID in vivo can often be associated with
anti-inflammatory events [47–49], and activation of PPARδ
in endothelial cells by snake venom PLA2-released PUFAs
can switch on the anti-inflammatory (rather than pro-
inflammatory) program [50]. However, it remains unclear
whether PUFAs released by mammalian sPLA2(s) from
lipoprotein particles would play an anti-inflammatory or
anti-atherosclerotic role.
sPLA2s and Atherosclerosis: in vivo studies
Expression of sPLA2s in atherosclerotic plaques
sPLA2-IIA is located in macrophage-rich regions, lipid
cores of atheromas, and the extracellular matrix of the
diseased intima in association with collagen fibers in
human atherosclerotic lesions [51]. sPLA2-V is also
enriched in atherosclerotic lesions of humans and experi-
mental animals, in which it is associated with smooth
muscle cells and also surrounding foam cells in lipid core
areas [52, 53]. A hyperlipidemic high-fat diet up-regulates
sPLA2-V expression in the aorta, and apoE
−/− x Ldlr
−/−
mice, in which atherosclerosis develops spontaneously,
show elevated aortic sPLA2-V expression [52]. sPLA2-X
is also immunohistochemically detected in atherosclerotic
lesions in both humans and apoE
−/− mice [37, 46]. In
humans, sPLA2-X is detected in the intima where it is
localized in the majority of foam cells and in phenotypi-
cally de-differenciated smooth muscle cells resembling
myofibroblasts as well as in the extracellular matrix, but
not detectable in T-lymphocytes and in the lesion-free areas.
sPLA2-III is focally expressed in advanced lesions of
atheroma in human and apoE
−/− mice, mainly in macro-
phages and smooth muscle cells [28]. Other sPLA2s (IID,
IIE, IIF) are also detected by immunohistochemistry and in
situ hybridization in human atheroslcerotic plaques, with
sPLA2-IIF exhibiting the most notable induction in accor-
dance with the developmental process of atherosclerosis
[54].
sPLA2-IIA
The principal experimental evidence for the potential role
of mammalian sPLA2 in atherosclerosis has arisen from
studies employing transgenic mice overexpressing human
sPLA2-IIA (PLA2G2A-Tg) [55], beyond the fact that the
C57BL/6 mouse strain intrinsically lacks sPLA2-IIA as a
result of a natural mutation of its gene [56]. PLA2G2A-Tg
mice maintained on high-cholesterol atherogenic diet
exhibit increased atherosclerotic lesions [55]. In these mice,
sPLA2-IIA is present in atherosclerotic lesions in the aorta,
and the plasma level of HDL is lower and that of LDL is
slightly higher in PLA2G2A-Tg mice than those in control
mice. Of importance, transplantation of bone marrow cells
from PLA2G2A-Tg mice into recipient Ldlr
−/− mice results
in a significant increase in the extent of atherosclerosis in
the aortic arch and sinus despite the absence of alteration in
lipoprotein composition, suggesting that macrophage-
derived sPLA2-IIA can exert a local pro-atherogenic effect
with enhancement of collagen deposition by a process
independent of systemic lipoprotein metabolism [57]. Thus,
even though the hydrolytic action of sPLA2-IIA on PC in
LDL and HDL is relatively low, it is still possible that only
local modification of lipoproteins by this enzyme within
vascularwallsissufficientfordevelopmentofatherosclerosis.
sPLA2-V
The findings that sPLA2-V can hydrolyze LDL- and HDL-
associated PC far more efficiently than does sPLA2-IIA and
that the LDL modified by sPLA2-V efficiently induces
macrophage foam cell formation, as described above, have
led to the idea that this enzyme is more important than
sPLA2-IIA for the promotion of atherosclerosis [58].
Importantly, Ldlr
−/− mice subjected to retrovirus-mediated
gene transfer of Pla2g5 cDNA have increased lesion area in
the ascending aortic root with a concomitant elevation of
regional collagen deposition, whereas mice transplanted
with bone marrow cells from Pla2g5
−/− mice show reduced
atherosclerosis in the aortic arch and thoracic aorta [53].
This result clearly indicates that sPLA2-V exerts a pro-
atherogenicfunctioninvivo.Surprisingly,however,reduction
of atherosclerotic lesion size is not evident in apoE
−/− mice
reconstituted with Pla2g5
−/− bone marrow cells, probably
because the lipoprotein lipid compositions are distinct
Fig. 3 HydrolysisofhumanHDL byrecombinant human sPLA2-III, -V
and –X in vitro. After HDL (1 mg/ml) was incubated with or without 10
or 50 nM sPLA2 for 4 h at 37°C, lipids were extracted and applied to
ESI-MS. Representative results of ESI-MS for choline-containing
phospholipids on a positive ion mode (a) and lysophospholipids on a
negative ion mode (b) are shown. Major peaks of PC, LPC, LPE and
SM molecular species are indicated. Asterisks indicate the peaks that
were significantly changed by addition of each sPLA2. Top-right graphs
show quantified data of LPC and LPE. For more details, please see [28]
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−/− and apoE
−/− backgrounds [59]. Never-
theless, the collagen content of the plaques is significantly
reduced in lesions of apoE
−/− mice lacking sPLA2-V. It
should be noted, however, that these bone marrow transplan-
tation approaches could assess the role of sPLA2-Vexpressed
only in macrophages or other hematopoietic cells. Hence, the
impact of sPLA2-V expressed in non-hematopoietic cells on
atherosclerosis still remains unknown. Of note, a recent
tagging single nucleotide polymorphism analysis has demon-
strated an association of the human PLA2G5, but not
PLA2G2A, gene haplotype with the plasma levels of LDL
and oxidized LDL in patients with type 2 diabetes [26].
sPLA2-X
sPLA2-X also potently hydrolyzes phospholipids in LDL
and HDL in vitro, with an effect even superior to that of
sPLA2-V (see above). A recent study has demonstrated that
the deficiency of sPLA2-X on the ApoE
−/− background
significantly reduces the incidence and severity of angio-
tensin II-induced abdominal aortic aneurysm and athero-
sclerosis, accompanied by reduction of pro-inflammatory
mediators [60]. Moreover, another study using Pla2g10
−/−
macrophages has provided an additional view that sPLA2-X
negatively regulates cholesterol efflux from macrophages
through altering the liver X receptor (LXR)-dependent
expression of ABC transporters [61]. These results support
the idea that sPLA2-X has a pro-atherogenic role in vivo. In
humans, however, non-synonymous polymorphism in the
PLA2G10 gene, which leads to a profound change in the
expression and activity of sPLA2-X, has no detectable
impact on cardiovascular disease risk, whereas another
polymorphism located in the 5′-untranslated region is
associated with a decreased, rather than increased, risk of
recurrent cardiovascular events [62]. Considering that
sPLA2-X can also exert an anti-inflammatory function
probably through producing anti-inflammatory PUFAs or
their metabolites [48], the mechanistic action of sPLA2-X
in atherosclerosis could not be simply explained only by
alterations in the lipoprotein modification. Further investi-
gation should be needed to elucidate the role of sPLA2-X.
To assess whether sPLA2-X has the capacity to hydro-
lyze lipoprotein PC in vivo, we examined the lipoprotein
profiles in plasma of transgenic mice overexpressing human
sPLA2-X (PLA2G10-Tg) [63] in comparison with littermate
wild-type (WT) mice. Plasma PLA2 activity, as evaluated
by release of [
14C]linoleic acid from 1-palmitoyl-2-[
14C]
linoleoyl-phosphatidylethanolamine,wasdramaticallyelevated
in PLA2G10-Tg mice over WT mice (Fig. 5a). sPLA2-X is
synthesized as an inactive pro-enzyme, and cleavage of the
N-terminal propeptide gives rise to a mature active enzyme,
which further undergoes N-glycosylation [64, 65]. Accord-
ingly, sPLA2-X proteins (mature, pro- and glycosylated
forms) were detected in the plasma of PLA2G10-Tg mice,
as assessed by immunoblotting using anti- sPLA2-X antibody
(Fig. 5b). Lipids were extracted from LDL and HDL of these
mice and subjected to ESI-MS for phospholipid analysis
(Fig. 5c–e). In both LDL and HDL, there were robust
increases in C16:0- and C18:0-LPC (Fig. 5d and e), with a
concomitant decrease in all PC molecular species (Fig. 5c), in
PLA2G10-Tg mice relative to WT mice. These results suggest
that sPLA2-X overexpressed in PLA2G10-Tg mice hydro-
lyzed LDL- and HDL-associated PC robustly in vivo.
It should be noted, however, that endogenous sPLA2-X
was undetectable in the plasma of WT mice (Fig. 5b), and
that we observed no difference in the lipoprotein compo-
sition between Pla2g10
−/− and littermate Pla2g10
+/+ mice
under physiological conditions [66]. Therefore, even
though the above study employing PLA2G10-Tg mice has
pointed that sPLA2-X has the capacity to hydrolyze
lipoprotein PC in vivo, its physiological importance
remains unclear. Presumably, under certain pathological
conditions, the expression level or proteolytic processing of
sPLA2-X is increased locally (e.g. in atherosclerotic
lesions), where it could contribute to hydrolysis of
lipoprotein PC. Indeed, a study using PLA2G10-Tg mice
has provided evidence that the proteolytic processing of
sPLA2-X is facilitated at inflamed sites [63].
sPLA2-III
sPLA2-III can efficiently hydrolyze PC in LDL and to a
lesser extent in HDL (see above). sPLA2-III-modified LDL,
like sPLA2-V- or sPLA2-X-treated LDL, facilitates the
formation of foam cells from macrophages ex vivo [28].
After intake of an atherogenic diet, aortic atherosclerotic
lesions are more severe in mice with transgenic over-
expression of human sPLA2-III (PLA2G3-Tg) than in
control mice on an apoE
−/− background [28]. In these
mice, plasma LDL and HDL are significantly hydrolyzed
by the enzyme, and peritoneal macrophages readily store
lipid droplets in the cytoplasm after exposure to LDL ex
vivo. Lipidomics studies demonstrate the elevation of LPC
as well as thromboxane A2 and 12-hydoxyeicosaenic acid,
which are arachidonate-derived products by activated
Fig. 4 Hydrolysis of human LDL and HDL by recombinant human
sPLA2-IIA, -IIE and –IIF in vitro. After LDL or HDL (1 mg/ml) was
incubated with or without 50 nM sPLA2 for 4 h at 37°C, lipids were
extracted and applied to ESI-MS. (a) Representative results of ESI-MS
for choline-containing phospholipids on a positive ion mode are shown.
Major peaks of PC, LPC, and SM molecular species are indicated on
the top. Asterisks indicate the peaks that were significantly changed by
addition of each sPLA2.( b) Quantified data of LPC in LDL (left)a n d
HDL (right) after incubation with each sPLA2 are shown. For more
details, please see [28]
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Interestingly, PLA2G3-Tg mice also develop systemic
inflammation [67], suggesting that the elevated inflammatory
state in the vascular wall may have an additional impact on
the promotion of atherosclerosis in these mice. Although
these observations suggest a potential functional link
between sPLA2-III and atherosclerosis, its pathological
relevance awaits further study employing Pla2g3
−/− mice.
Pharmacologic effect of sPLA2 inhibitor
on atherosclerosis
Accumulating evidence as mentioned above suggests that
sPLA2 may represent a novel target for atherosclerosis and
associated cardiovascular diseases. The potent sPLA2
inhibitors, which broadly inhibits sPLA2s in the group I/
II/V/X branch at low nM potency in vitro, include the
Fig. 5 Altered lipoprotein profiles in PLA2G10-Tg mice. (a and b)
PLA2 enzymatic activity was markedly elevated (mean ± S.D., n=4,
*p<0.05) (a) and sPLA2-X proteins (mature, precursor- and glycosy-
lated forms) were detectable by immunoblotting with anti-sPLA2-X
antibody (b) in 8-wk-old PLA2G10-Tg (X-Tg) mice. Top panel in (a)
shows the expression of the PLA2G10 transgene in PLA2G10-Tg
mice, as assessed by RT-PCR using a primer set that amplified the
full-length PLA2G10.( c–e) ESI-MS analysis of choline-containing
phospholipids in lipoprotein particles from WT and X-Tg mice.
Individual PC molecular species in HDL of PLA2G10-Tg and WT
mice were quantified (c). Representative ESI-MS spectra of LDL (d)
and HDL (e) particles purified from WT (left) and X-Tg (right) mice
are shown. Major peaks of PC, LPC, and SM molecular species are
indicated on the top. In both LDL and HDL, peaks of LPC species
were markedly increased in X-Tg mice compared with WT mice
1838 K. Yamamoto et al.functionalized indole scaffolds, such as indoxam, methyl-
indoxam and LY315920, from Eli Lilly and Shionogi [68].
The development of these compounds involves structure-
guided improvement of binding capacity starting with a
lead compound obtained through high-throughput screening
and making use of the X-ray structure of human sPLA2-IIA
[69]. Interestingly, A-002 (1-H-indole-3-glyoxamide or
varespladib), a lead compound of this pan-sPLA2 inhibitor
series, can decrease the area of atherosclerotic lesions
dramatically, accompanied by a 1.4-fold increase in HDL,
in apoE
−/− mice fed a high-fat diet [70–72]. Combinational
treatment of animals with pravastatin (a member of the drug
class of statins (HMG-CoA reductase inhibitors)) and A-002
decreases the lesion area and plasma cholesterol level even
more, suggesting a synergistic effect between the two agents
in amelioration of atherosclerosis through decreased levels of
systemic inflammation or circulating lipids. A-002 treatment
also stabilizes the plaque architecture. Because apoE
−/− mice
(C57BL/6 background) intrinsically lack sPLA2-IIA due to a
natural mutation [56], the anti-atherosclerotic effect of A-002
could be attributable to the inhibition of other sPLA2
isoforms, probably sPLA2-V or –X (note that A-002 does
not inhibit sPLA2-III, an atypical sPLA2). Furthermore, a
phase II double-blind, randomised, placebo-controlled trial
to assess the effects of A-002 in human patients with
coronary heart disease has demonstrated that the serum
concentration of sPLA2 (most likely sPLA2-IIA), as well as
the levels of vascular (oxidized LDL) and general (C-
reactive protein) inflammation markers, decreases progres-
sively to nearly an order of magnitude less than the baseline,
with no increase in adverse events [73]. A-002 also reduces
the concentration of LDL cholesterol and the number of
LDL particles, mainly by reducing small-dense LDL. Thus,
A-002 shows promising reduction of biomarkers and effects
on surrogate endpoints, encouraging further investigation of
whether it can reduce cardiovascular disease events without
any other off-target toxicity. Although it is uncertain whether
A-002 exerts its anti-atherosclerotic effect in humans by
inhibiting circulating sPLA2-IIA, plaque-associated sPLA2-
V and -X, or both, these animal and early-phase clinical
studies nevertheless suggest that sPLA2s could be exciting
therapeutic targets for atherosclerosis.
Concluding Remarks
Inthisarticle,wehavehighlightedacurrentviewoftheroleof
sPLA2s in lipoprotein hydrolysis and atherosclerosis. Need-
less to say, MS-based lipidomics has greatly contributed to
expanding our understanding of sPLA2-mediated hydrolysis
of lipoprotein phospholipids. sPLA2s have also been
implicated in various biological processes, such as asthma,
arthritis, cancer, antimicrobial defense and reproduction,
among others [1, 2]. However, therapeutic or prophylactic
efficacies of the sPLA2 inhibitors should be carefully
evaluated, since gene targeting of several sPLA2sh a v e
revealed that distinct isoforms often display opposite
functions in a given pathology [47]. In this sense, inhibition
of multiple sPLA2s altogether could inhibit both offensive
and defensive sPLA2 isozymes and thereby cancel the
therapeutic effect resulting from the inhibition of the pro-
inflammatory one(s), as has been seen for human rheumatoid
arthritis in which a pan-sPLA2 inhibitor had no beneficial
effect [74]. Thus, using an inhibitor that specifically blocks
only the offensive sPLA2 may be a more desirable strategy
than using the currently tested pan-sPLA2 inhibitors that
block group I/II/V/X sPLA2s altogether. Nonetheless, all the
above knowledge, together with application of lipidomics to
in vivo systems, should help proper identification of certain
PLA2s and their target phospholipids or their metabolites as
therapeutic targets or as novel biotherapeutic molecules in
various diseases including atherosclerosis.
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